| Literature DB >> 35629089 |
Yutaka Shimada1, Tetsuo Sudo1, Shusuke Akamatsu2, Takuro Sunada2, Akira Myomoto1, Kiyoshi Okano1, Kazuharu Shimizu1.
Abstract
The importance of circulating tumor cells (CTC) is well recognized. However, the biological characteristics of CTC in the bloodstream have not yet been examined in detail, due to the limited number of CTC cell lines currently available. Thirty-nine CTC cell lines were reported by 2021. For successful cell culturing, these CTC cell lines were reviewed. Previous studies on short-term cultures of CTC also analyzed approaches for establishing the long-term culture of CTC. Negative selection, hypoxic conditions, three-dimensional conditions, and careful management are preferable for the long-term culture of CTC. However, the establishment of CTC cell lines is dependent on the specific characteristics of each cell type. Therefore, a method to establish CTC cell lines has not yet been developed. Further efforts are needed to resolve this issue.Entities:
Keywords: cell line; circulating tumor cell; long-term culture; short-term culture
Year: 2022 PMID: 35629089 PMCID: PMC9148030 DOI: 10.3390/jpm12050666
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Summary of CTC cell lines.
| Cell Line | Type of Cancer | Establishing Rate | Culture Period or Passage | Doubling Time | Xenograft | Specific Characteristics | References |
|---|---|---|---|---|---|---|---|
| CTC-1, CTC-2, CTC-3 | Breast cancer | 3/38 | Several passages? | N/A | Yes (all 3 CTC lines) | EpCAM(−) | Zang et al. (2013) [ |
| BRx33, BRx07, BRx68, BRx50, BRx42, BRx61 | Breast cancer | 6/36. Several cell lines from the same patient at different times | >6–12 months | 3 days to 3 weeks | Yes (3 out of 5 CTC cells lines) | ER(+), PIK3CA, TP53, KRAS, FGFR2 | Yu et al. (2014) [ |
| MSK-PCa5 | Prostate cancer | 1/17 | Passage was performed weekly at a 1:3 ratio | 1 week | Yes | CK(+), AR(+),High PSA, PTEN(−), RB(−) | Gao et al. (2014) [ |
| CTC-MCC-41 | Colon cancer | 1/50 (CTC-positive patients) | >16 months | 20 h | Yes | EpCAM(+), Snail, ALDH1, CD133, | Cayrefourcq et al. (2015) [ |
| BHGc7, BHGc10 | Small cell lung cancer | 2/30 | >4 months. Long-term culture was confirmed by two follow-up studies | N/A | Yes | Carbonic anhydrase (CAIX) | Hamilton et al. (2015) [ |
| N/A (one line was named CTC-TJH-01 by Que [ | Lung adenocarcinoma | 2/35 | >6 months | N/A | N/A | Wang et al. (2016) [ | |
| BHGc16, BHGc26, UHGc5 | Small cell lung cancer | N/A | N/A | N/A | N/A | CD133, CD24, SOX-2 | Klameth et al. (2017) [ |
| CTC44, CTC45 (both established from the same patient) | Colorectal cancer | 3/4. Several cell lines from the same patient at different times | >20 passages | N/A | Yes | CD133, CD26, ALDH1A1, CD44 | Grillet et al. (2017) [ |
| BRx82, BRx142 | Breast cancer | N/A | N/A | 101.2 and 59.7 h | N/A | Able to cryopreserve | Sandlin et al. (2017) [ |
| CTC-MCC-41.4, 41.5A. 41.5B. 41.5C, 41.5D. 41.5E, 41.5F, 41.5G (established from the same patient) | Colon cancer | N/A. Several cell lines from the same patient at different times (8 cell lines) | N/A | N/A | N/A | ALDH1, CD44, panCD66, EpCAM | Soler et al. (2018) [ |
| CTC-TJH-01 | Non-small cell lung cancer | 1/89 | 24 months | N/A | Yes | CXCL5, CD44, ALDH1 | Que et al. (2019) [ |
| CTC-3 | Breast cancer | 1/16 | >2 years | N/A | Yes | CD44 | Zhao et al. (2019) [ |
| CTC-ITB-01 | Breast cancer | 1/50 | >4 years | N/A | N/A | E-Cadherin, EpCAM, K19, CD24, Twist 1 | Koch et al. (2020) [ |
| UWG01CTC, UWG02CTC | Gastroesophageal cancer | 2/23 | >12 months | N/A | Yes | EpCAM(−), CD56, (UWG01CTC) or EpCAM(+), CK(+), CD44, E-Cadherin | Brungs et al. (2020) [ |
| Mel-167, PEM-22, Mel-182, PEM-78 | Melanoma | 4/37. Several cell lines from the same patient at different times (Mel 182-1, Mel 182-2) | N/A | N/A | Yes | BRAF-mutant NG-2, MLANA | Hong et al. (2021) [ |
| EMC-Pca-41 | Prostate cancer | 1/40 | >1 year, 10 passages | N/A | N/A | TMPRSS2-ERG fusion, loss of PTEN | Mout et al. (2021) [ |
N/A: not available.
Culture protocols of CTC cell lines.
| Cell Line | Blood Volume | CTC Count/mL | CTC Enrichment and Isolation | Culture Type | Environment | Culturing Conditions | Culture Medium | References |
|---|---|---|---|---|---|---|---|---|
| CTC-1, CTC-2, CTC-3 | 20 to 45 mL | Undetectable by CellSearch | FACS (CD45, ALDH1, EpCAM) | 2D. single cell to colony formation | 5% CO2. Normoxic conditions | Adherent (1–8 days), medium change (8–21 days). The EpCAM(−)/ALDH1(+)/CD45(−) population was transferred to 24- or 6-well plates | Stem cell culture medium. Insulin, hydrocortisone, B-27, EGF, FGF-2, (1–8 days). EpiCult-C medium supplemented with 10% FCS (8–21 days). DMEM/F12 supplemented with 10% FCS (from day 22) | Zang et al. (2013) [ |
| BRx33, BRx07, BRx68, BRx50, BRx42, BRx61 | 6 to 18 mL | 3–3000/6 mL | CTC iChip | 3D Spheroid | 4% O2 | Ultra-low attachment plate. Medium changes were performed under a microscope | Serum-free, EGF, FGF, B-27 | Yu et al. (2014) [ |
| MSK-PCa5 | 8 mL | >100 count/8 mL | RosetteSep CD45-depleted Cocktail | 3D Organoid. Start to grow as spheroids after 10 days | N/A | Matrigel | DMEM/F12, EGF, R-spondin 1, Noggin, FGF10, FGF2, DHT, Nicotinamide Acros, A83-01, SB202190, Y-27632, B27, N-Acetyl-L-cysteine, Glutamax, HEPES, Primocin | Gao et al. (2014) [ |
| CTC-MCC-41 | 10 mL | 302 count/7.5 mL | RosetteSep CD45-depleted Cocktail | 3D Spheroid | Initial environment: 2% O2. Maintenance: 5% CO2, Normoxic conditions | 24-well non-adherent plate. T25 flask (maintenance) | Initial medium: Stem cell culture medium, DMEM/HamF12 2% FCS, insulin, N2 component, EGF, L-Glutamine, FGF2. Second medium: RPMI1640 EGF, FGF2, insulin-transferrin-selenium supplement, L-Glutamine. Maintenance: N/A | Cayrefourcq et al. (2015) [ |
| BHGc7, BHGc10 | N/A | N/A | Ficoll-Hypaque density gradient | 3D and 2D | Normoxic conditions | 12-well adherent plate. Normoxic conditions | Initial medium: Serum-free, RPMI-1640, insulin, IGF-1, transferrin, selenite, Maintenance: RPMI-1640, 10% FCS | Hamilton et al. (2015) [ |
| N/A (one line was named as CTC-TJH-01 in Que Z paper [ | 2 mL | 130 count/2 mL | Microfluidics-based immunomagnetic isolation. EpCAM coated and EGFR coated immunomagnetic microbeads | N/A | 3% O2, 5% CO2 (1–14 days). 5% CO2 Normoxic conditions | 96-well non-adherent plate. | Initial medium: RPMI1640, EGF, FGF, B27. Maintenance: RPMI-1640, 10% FCS | Wang et al. (2016) [ |
| BHGc16, BHGc26, UHGc5 | N/A | N/A | N/A | 3D and 2D | Normoxic conditions | N/A | Initial medium: N/A. Maintenance: RPMI-1640, 10% FCS | Klameth et al. (2017) [ |
| CTC44, CTC45 (both established from same patient) | 8–10 mL | N/A | RosetteSep CD45-depleted Cocktail | 3D | N/A | Ultra-low attachment 24-well plate | DMEM/F12, 2% FCS, L-Glutamine, N2 supplement, EGF, FGF2 | Grillet et al. (2017) [ |
| BRx82, BRx142 | N/A | N/A | N/A | 3D | N/A | 6-well ultra-low adhesion plate | Initial medium: N/A, Maintenance: RPMI1640 EGF, FGF2, B-27 | Sandlin et al. (2017) [ |
| CTC-MCC-41.4, 41.5A. 41.5B. 41.5C, 41.5D. 41.5E, 41.5F, 41.5G, (established from same patient) | 10 mL | 286/7.5 mL–3278/7.5 mL | RosetteSep CD45-depleted Cocktail | 3D | N/A | 24-well non-adherent plate (1st week). New 24-well non-adherent plate (2nd week). T25 flask (maintenance) | RPMI 1640, EGF, FGF-2, insulin-transferrin-selenium supplement, L-Glutamine | Soler et al. (2018) [ |
| CTC-TJH-01 | 5 mL | 130 count | A mixture of EpCAM and EGFR coated immunomagnetic microbeads in microfluidic Herringbone-Chip | 2D | N/A | Non-adherent plate | Initial medium: RPMI1640, EGF, FGF, B27. Maintenance: RPMI-1640, 10% FCS | Que et al. (2019) [ |
| CTC-3 | 6 mL | N/A | RosetteSep CD45-depleted Cocktail | 2D | Normoxic conditions, 5% CO2 | 6-well Matrigel-coated plate (2 weeks), normal 6-well plate (medium change every 2–3 days). Final culture in a T25 flask | DMEM/RPMI1640, 10% FCS, EGF, FGF, Nu-Serum, L-Glutamine | Zhao et al. (2019) [ |
| CTC-ITB-01 | 7.5 mL | 1547/mL | RosetteSep CD45-depleted Cocktail | 3D and 2D | Normoxic conditions, 5% CO2 (1–14 days) | 96-well normal plate, then transferred to a 12-well culture dish | RPMI1640 10% FCS, L-Glutamine, insulin-transferrin selenium-A, FGF2, EGF, hydrocortisone, cholera toxin | Koch et al. (2020) [ |
| UWG01CTC, UWG02CTC | 15 mL | 3/mL (UWG01CTC), 109/mL (UWG02CTC) | RosetteSep CD36-depleted Cocktail | 2D or 3D | Normoxic or hypoxic conditions | 24-well ultra-low attachment plate | DMEM/F12, EGF, FGF, N2 supplement (normoxic conditions) or DMEM/F12, 10% FCS (hypoxic conditions) | Brungs et al. (2020) [ |
| Mel-167, PEM-22, Mel-182, PEM-78 | 10 mL | N/A | CTC iChip | 3D | Hypoxia, 5% CO2, 4% O2 | 24-well ultra-low attachment plate (4–8 weeks). Use of a 3D fibrin Matrigel culture. Finally, a switch to an anchorage-independent culture | RPMI 1640, EGF, FGF2, B-27, Heparin, Y-27632 | Hong et al. (2021) [ |
| EMC-PCa-41 | 5 L | 5312/96 mL | Leukapheresis, RosetteSep CD45-depleted Cocktail | 3D Organoid | Normoxic conditions | 24-well plate Matrigel droplets. Organoids were collected and resuspended in a new plate | Initial medium: Prostate growth medium (PGM) or adjusted prostate cancer organoid medium (APCOM). Maintenance: AdMEM/F12 | Mout et al. (2021) [ |
EGF: Epidermal growth factor, FGF: Fibroblast growth factor.
Summary of short-term cultures.
| Research Group | Cancer Type | Establishing Rate | CTC Count | CTC Detection | Culture Period | Additional Information |
|---|---|---|---|---|---|---|
| Makino et al. (1999) [ | Gastrointestinal cancer | 4/20 | 1–123/mL by cytospin | HEA(+), CK(+) | 14 days | High CTC were more likely to form spheroids |
| Paris et al. (2009) [ | Prostate cancer | 5/8 | 150–740/mL (CRPC), 0–100/mL (CSPC) | Pan CK(+), CD45(−), EpCAM | 1 week to 3 months | |
| Lu et al. (2010) [ | Breast cancer | 10/10 | 18–256/mL | EpCAM, Pan CK, CD45 | 1–33 days | Collagen adhesion matrix (CAM) |
| Pizonet al. (2013) [ | Breast cancer | 31/39 | 1700–9360/mL | EpCAM(+) | 28 days | Number of spheres was 0–29/mL |
| Bobek et al. (2014) [ | Pancreatic cancer | 16/24 | NA | Nuclear size, NC ratio, Irregularity, CK7, DAPI, CD45(−) | >14 days | |
| Bobek et al. (2014) [ | Esophageal cancer | 27/43 | NA | Nuclear size, NC ratio, Irregularity, CK18, DAPI, CD45(−) | <14 days | |
| Bobek et al. (2014) [ | Pleural Mesothelioma | 4/5 | NA | Nuclear size, NC ratio, Irregularity, MPF, OPN, DAPI, CD45(−) | 10–14 days | |
| Ceganet et al. (2014) [ | Urinary bladder cancer | 25/39 | 1–50/8 mL | Nuclear size, NC ratio, Irregularity, CK18, DAPI, CD45(−) | 14 days | |
| Kolostova et al. (2014) [ | Urothelial tumors | NA | NA | Nuclear size, NC ratio, Irregularity, CK7, DAPI | 10 to 14 days | |
| Kolostova et al. (2014) [ | Prostate cancer | 18 (proliferative capacity)/28 (CTC-positive)/55 (total cases) | NA | Nuclear size, NC ratio, Irregularity, CK7, DAPI | 14 days | |
| Sheng et al. (2014) [ | Pancreatic cancer | 0/12 | 0–7/mL | CK(+), CD45(−), DAPI | no proliferation | Capture and release |
| Zhang et al. (2014) [ | Lung cancer | 14/19 | 1 to 11/mL | CK(+), CD45(−) | NA | p53 mutation did not always match between primary tissue and CTC |
| Khoo et al. (2015) [ | Breast cancer | 7/18 (early stage) | NA | CK(+), CD45(−) | 2–8 weeks | |
| Kolostova et al. (2015) [ | Ovarian cancer | 77/118 | NA | Nuclear size, NC ratio, Irregularity, CK, DAPI, CD45(−) | 3–14 days | CA125-positive |
| Kolostova et al. (2015) [ | Gynecological cancer | 3/3 | NA | Nuclear size, NC ratio, Irregularity, CK7, DAPI, CD45(−), Muc1 | 3–10 days | |
| Chen et al. (2016) [ | Colorectal cancer | NA | 0–1000/mL | DAPI, CK20(+), CD45(−) | 10 days to 2 months | Maintenance for up to 2 months, but no growth was observed. p53 mutation, APC |
| Kolostova et al. (2016) [ | Gastric cancer | 13/22 | NA | Nuclear size, NC ratio, Irregularity, CK18, 19, DAPI, CD45(−) | >14 days | |
| Kulasinghe et al. (2016) [ | Head and neck cancer | 7/25 | 1–15 CTC/5 m by cytospin | EpCAM(+), CK(+) CD45(−), morphologically larger than background cells. High NC ratio | 21 days to 63 days. 3D is longer than 2D | Successfully obtained higher CTC counts. HPV-positive |
| Malala et al. (2016) [ | Colon cancer | 7/7 | 5/mL (CD133(+)), 29/mL (CK20(+)) | CK20(+), CD45(−) | 14 days | The characterization of CTC revealed changes in their phenotypes during their cultivation in vitro |
| Zhang et al. (2016) [ | Hepatocellular carcinoma | 31/36 (>100 μm defined as spheroids) | 1–42/2 mL | ASGPR, CK(+), CD45(−) | >7 days | Capture and release. ASGPR(+) |
| Eliasova et al. (2017) [ | Colorectal cancer | 81/98 | NA | Nuclear size, NC ratio, Irregularity, CK, DAPI, CD45(−) | 3–5 days, some were able to grow for 6 months | |
| Lambros et al. (2018) [ | Prostate cancer | 2/14 | 12546/7.5 mL | DAPI, CK(+), CD45(−) | >4–6 weeks | Two organoids from the same patient |
| Franken et al. (2019) [ | Breast cancer | 2/8 (without cryopreserved samples), 3/9 (cryopreserved samples) | 1–2913 CTC/7.5 mL | CK(+), CD45(−) | >3 months | Successfully cultured from cryopreserved samples |
| Kapeleris et al. (2020) [ | Non-small cell lung cancer | 9/70 | 0–385/7.5 mL | DAPI, CK(+), CD45(−), high NC ratio, larger than background cells | 20 to 50 days | Culturability was not affected by an increased number of CTC. EGFR mutation |
| Lee et al. (2020) [ | Small cell lung cancer | 18/22 | 8–277/mL | CK(+), CD45(−), EpCAM, TTF-1, Synaptophysin | 2 to 6 weeks | BCC, Platelet lysate |
| Xiao et al. (2020) [ | Breast cancer | 12/12 | NA | CK5, CK8, Mammaglobin | >30 days (6 cases), <30 days (6 cases) | Presence of CD45(+) cells exhibited higher growth potential ex vivo. Does not exclude CD45(+) cells |
| Carmona-Ule et al. (2021) [ | Breast cancer | 36/50 | 0−1000/7.5 mL | EpCAM, Pan CK, CD45 | >23 days (up to 291 days, mean 8 weeks) | Nanoemulsions support CTC. Some cells express CD45 (+), CD36(+) |
| Hu et al. (2021) [ | Hepatocellular carcinoma | 55 (spheroid)/60 (CTC)/106 (total) | NA | ASGPR/CPS1, DAPI, EpCAM, CD45(−) | 12–14 days | Beta-catenin (+), a spheroid was defined as a 3D cell structure >100 μm. ASGPR(+) |
| Yang et al. (2021) [ | Gastrointestinal cancer | 13 (colony)/38 (viable cell)/81 (total) | NA | hTERT | 4 weeks | J2 feeder cell-coated plate |
HEA: Human epithelial antigen. CRPC: Castration-resistant prostate cancer. CSPC: Castration-sensitive prostate cancer. ASGPR: Asialoglycoprotein receptor 1.
Protocol for the short-term culture.
| Authors | Blood | CTC Enrichment and Isolation | Culture Type | Environment | Culture Condition | Culture Medium |
|---|---|---|---|---|---|---|
| Makino et al. (1999) [ | 30 mL | Magnetic cell sorting system (MACS) anti-HEA125 (EpCAM) | 2D semi-spheroid | 37 °C, 5% CO2 | 60 mm culture dish | RPMI1640/F12, 10% FCS |
| Paris et al. (2009) [ | 3 mL | Ficoll-Paque | 2D | N/A | 16-well chamber slide coated with Collagen adhesion matrix (CAM) | DMEM/RPMI1640, 10% FCS, Nu-serum, L-glutamine |
| Lu et al. (2010) [ | 0.5 mL | Ficoll density gradient centrifugation, Collagen adhesion matrix (CAM) capture | 2D | 37 °C, 5% CO2 | CAM-coated 96-well microtiter plate | RPMI1640, 10% FCS, Nu-serum, L-glutamine |
| Pizon et al. (2013) [ | 1 mL | Erythrocyte lysis | 3D | 37 °C, 5% CO2 | 25 cm2 culture flask | RPMI1640, low FCS, L-glutamine, EGF, Insulin, Hydrocortisone |
| Bobek et al. (2014) [ | 8 mL | MetaCell: filtration using a porous polycarbonate membrane (pores with a diameter of 8 μm) | 2D | 37 °C, 5% CO2 | On the membrane and bottom of the 6-well culture plate | RPMI1640, 10% FCS |
| Cegan et al. (2014) [ | 8 mL | MetaCell: filtration using a porous polycarbonate membrane (pores with a diameter of 8 μm) | 2D | 37 °C, 5% CO2 | On the membrane and bottom of the 6-well culture plate | RPMI1640, 10% FCS |
| Kolostova et al. (2014) [ | 8 mL | MetaCell: filtration using a porous polycarbonate membrane (pores with a diameter of 8 μm) | 2D | 37 °C, 5% CO2 | On the membrane and bottom of the 6-well culture plate | RPMI1640, 10% FCS |
| Sheng et al. (2014) [ | 5–10 mL | GEM chip | 2D | 37 °C, 5% CO2 | 60 mm culture dish | DMEM, 10% FCS |
| Zhang et al. (2014) [ | 5 mL | Microfluidic CTC capture chip | 3D | 37 °C, 7.5% CO2 | On chip co-culture (fibroblast) 7 days. Well plate for 7 days | RPMI complete medium, 10% FCS |
| Khoo et al. (2015) [ | 10 mL | RBC lysis | 3D spheroid | 37 °C, 5% CO2, 1% O2. Normoxic conditions (maintenance) | Tapered microwell (14 days). 3D (Geltrex) ultra-low adhesive dish | DMEM, 10% FCS. Then, DMEM/F12, reduced serum |
| Chen et al. (2016) [ | 2 mL | Lipid bilayer-coated microfluidic system (CMx platform) EpCAM, gentle sweep of air foam | 2D and 3D | N/A | Normal attachment culture dish or ultra-low attachment plate | DMEM medium, EGF, FGF, Insulin, B-27 |
| Kulasinghe et al. (2016) [ | 10 mL | RosetteSep CD45-depleted Cocktail | 2D and 3D | 2% O2, 5% CO2 | 96-well standard microplates, Spheroid microplates, Happy Cell® hydrogel for 3D expansion | DMEM/F12, EGF, R-Spondin, Noggin, FGF10, FGF2, Nicotinamide, A83-01, SB202190, Y-27632, B27, N-Acetyl-L-cysteine, Glutamax, Hepes, Primocin |
| Malala et al. (2016) [ | 5 mL | Ficoll-Paque | 3D sphere | N/A | Culture dishes | DMEM/F12, Heparin, EGF, FGF, BSA |
| Zhang et al. (2016) [ | 2 mL | Microfluidic chip, Capture and release | 3D Gel | 37 °C | Matrigel 24-well plate | DMEM: Matrigel 1:1, 10% FCS |
| Eliasova et al. (2017) [ | 8 mL | MetaCell: filtration using a porous polycarbonate membrane (pores with a diameter of 8 μm) | 2D | 37 °C, 5% CO2 | On the membrane and bottom of the 6-well culture plate | RPMI1640, 10% FCS |
| Lambros et al. (2018) [ | 40 to 100 mL | Apheresis, EasySep EpCAM-positive selection | 3D organoid | N/A | Ultra-low attachment surface-coated microplates | Growth factor-reduced Matrigel |
| Franken et al. (2019) [ | 3.41 L | Diagnostic Leukapheresis (DLA), microfluidic Parsortix system | 3D | 5% CO2, 4% O2 | Low attachment plate | Tumor sphere medium, RPMI1640, B27, EGF, FGF, |
| Kapeleris et al. (2020) [ | 10 mL | RosetteSep CD45-depleted Cocktail, RBC lysis | N/A | 1–2% O2 | 96-well standard microplates | DMEM/F12, EGF, R-Spondin, Noggin, FGF10, FGF2, Nicotinamide, A83-01, SB202190, Y-27632, B27, N-Acetyl-L-cysteine, Glutamax, Hepes, Primocin, 10% FCS |
| Lee et al. (2020) [ | 7.5 mL | RosetteSep | 2D and 3D | N/A | 96-well binary colloid crystal (BCC) substrate | DMEM/F12, EGF, bFGF, B27, Platelet lysate |
| Xiao et al. (2020) [ | 7.5 mL | Ficoll-Paque | 2D | 37 °C | Culture dishes | DMED/F12 B27, EGF, FGF, Heparin, Y-27632, Adenine, L-Glutamine |
| Carmona-Ule et al. (2021) [ | 7.5 mL | RosetteSep CD56-depleted Cocktail | 3D | 37 °C, 5% CO2, 1–2% O2 (1 week). Then, normoxic conditions | 96-well ultra-low attachment plate. Then, 24-well ultralow attachment. 25T flask (maintenance) | MammoCult media, Progesterone, Beta-estradiol, Heparin, Hydrocortisone, UltraGRO, B-27, bFGF, EGF, Nanoemulsions |
| Hu et al. (2021) [ | 5 mL | Ficoll-Paque, CD45 depletion by magnetic separation | 3D Gel | 37 °C, 5% CO2 | 24-well plate | DMEM, Matrigel, 10% FCS |
| Yang et al. (2021) [ | 5 mL | RBC lysis | 2D | 37 °C, 5% CO2 | J2 feeder cell-coated plate | DMEM, 5% FCS, L-glutamine, F12 nutrient mix, Hydrocortisone, EGF, Insulin, Cholera toxin Y-27632 |
Figure 1Representative images of the short-term CTC cell culture. (a) Cytospin image. Positive staining for Human Epithelial Antigen (HEA) was observed in cell clusters on day 7. (b) Phase contrast image of cell clusters on day 14 using a green filter [7].
Figure 2Colony formation by 4 out of 20 samples. The number of samples was too small for a definite evaluation; however, a high CTC count/mL (anti-HEA) was associated with colony formation (an unpaired t-test and the Mann–Whitney U test < 0.05) [7].
Figure 3CK/CD45 double positive cells. Cells obtained from the short-term (35 days) CTC culture. Cytospin image: (a) Merge, (b) DAPI, (c) CK, and (d) CD45. The scale bar shows 150 μm. Some cells express both CK and CD45.
Figure 4Morphology of double positive cells. These cells were large, polymorphic, and polynuclear, which suggested that they were tumor–macrophage fusion cells (TMFs), macrophage–tumor cell fusion cells (MTFs), or cancer-associated macrophage-like (CAMLs) cells. The scale bar shows 150 μm. White arrows indicate CK/CD45 double positive cells.
Protocol currently recommended for CTC cell lines.
|
|
| (1) Blood sample volume >10 mL |
| (2) Negative selection for CTC enrichment (RosetteSep®, etc.) or Ficoll-Paque density gradient centrifugation |
| (3) Hypoxic conditions within 10 days (7 days is recommended) |
| (4) Low attachment plate or gel formation |
| (5) Growth factors (such as EGF, FGF, and B-27) and anti-apoptotic supplements (including Y-27632) with FCS |
|
|
| (1) Preservation of CD45(+) cells. |
| (2) Normoxic conditions and attachment plates dependent on the cell type |
| (3) Microfluidic device or nanotechnology-based method |
| (4) Serum-free medium |
| (5) Co-culture with normal leukocytes or fibroblasts |
| (6) Culture medium changes under the microscopic ministering of cell clusters |
| (7) Exclusion criteria |
| (i) the use of chemotherapy and/or antibody-based therapy in the past 4 weeks |
| (ii) the use of radiotherapy in the past 2 weeks |
|
|
| (1) Transfer to normoxic conditions |
| (2) Standard culture medium |
|
|
| (1) No standard method |
| (2) Select specific conditions depending on each cell |
| (3) Careful management |
|
|
| (1) Medium changes at 200 μL/min or less every 72 h [ |
| (2) In the case of a highly proliferative culture, an increased frequency of medium changes |
| (3) To prevent the excessive stimulation of normal blood cells, the use of anti-apoptotic supplements for long periods is not recommended |